Safety and Tolerability of "Ready-to-Use" (SOMAKIT TOC®) 68Ga-DOTA0-Tyr3-Octreotide (68Ga-DOTATOC) for Injection in Patients with Proven Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs) Abstract #1759

Introduction: 68Ga-DOTATOC (PET) has superior diagnostic performance than Octreoscan (SPECT) in patients with GEP-NETs.
Aim(s): A new “ready-to-use” 68Ga-DOTATOC formulation for injection aims to simplify the synthesis of the final radiotracer.
Materials and methods: This phase I/II multicentre, open label study assessed the safety and tolerability of a single dose of 68Ga-DOTATOC (prepared on the day of the scan; product stability: 4 hours) 2 MBq/kg ± 10% (range 100-200 MBq) in patients with biopsy-proven grade 1-2 GEP-NETs. PET-CT imaging was performed 40-60 minutes post injection. Patients were followed-up for 28 days for safety/ tolerability assessment.
Conference: 14th Annual ENETS conference (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr Angela Lamarca
Keywords: SomaKit, DOTATOC, GEP-NET

To read results and conclusion, please login ...

Further abstracts you may be interested in

#887 Detection Limitation of Occult NET Using Gallium-68 Dotatoc Scan Plus FDG PET
Introduction: The modalities detection of gastroenteropancreatic neuroendocrine tumors (GEP-NET) includes sonogram, abdominal CT and MRI, but the detection rate is limited. Iodium-111 Octreotide scan is another choice. Ga-68 Dotatoc scan is very rapid and more sensitive than Octreoscan. The Ga-68 Dotatoc scan plus FDG-PET is useful for detecting active NETs.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Professor Tsann Long Hwang
#1306 The Role of Ga68-DOTATOC-PET-CT in Routine Screening of Multiple Endocrine Neoplasia Type 1
Introduction: Multiple endocrine neoplasia type 1 is a tumor syndrome characterized by NENs of the pancreas, duodenum, parathyroid, pituitary, adrenal, thymus and bronchi. Gene carriers are recommended participation in prospective screening programs at expert centers. Ga68-DOTATOC-PET-CT is an increasingly used very sensitive imaging technique for GEP-NENs.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr. Max Benjamin Albers
#1529 Somatostatin Receptor PET/CT with Radiolabelled Antagonist Is Twice as Effective as the Agonist for Detecting Liver Metastases: Results of a Phase 1/2 Study Comparing 68Ga-OPS202 with 68Ga-DOTATOC PET/CT in Gastroenteropancreatic NET Patients
Introduction: 68Ga-DOTATOC PET/CT is a reference method for imaging somatostatin receptor (sstr) expressing neuroendocrine tumors (NET). Presence and extent of liver metastases impact on patient management and prognosis.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Guillaume Nicolas
#1563 Impact of Early Surgery on Prognosis in Advanced Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET)
Introduction: In gastro-entero-pancreatic neuroendocrine tumours (GEP-NET) the role of surgery remains to be determined.
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: MD Patrizia Kump
#1316 Validation of Lysyl Oxidase-Like 2 (LOXL2) as Prognostic Marker for Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NET) Using an Independent Cohort.
Introduction: LOXL2 is a key protein to epithelial to mesenchymal transition. We showed LOXL2 has a role as a prognostic marker in 115 GEP-NET cases (training cohort (TC)).
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Dr. Jorge Barriuso
Keywords: LOXL2